Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 4
1980 8
1981 4
1982 2
1983 6
1984 5
1985 3
1986 5
1987 6
1988 9
1989 7
1990 6
1991 3
1992 6
1993 3
1994 6
1995 3
1996 6
1997 12
1998 15
1999 10
2000 6
2001 10
2002 9
2003 15
2004 21
2005 19
2006 23
2007 24
2008 33
2009 37
2010 42
2011 37
2012 52
2013 48
2014 52
2015 56
2016 77
2017 91
2018 140
2019 107
2020 129
2021 160
2022 181
2023 188
2024 162
2025 187
2026 87

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,882 results

Results by year

Filters applied: . Clear all
Page 1
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, Vollan HK, Peters S. Lee SM, et al. Among authors: le at. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.
What Causes Premature Coronary Artery Disease?
Le A, Peng H, Golinsky D, Di Scipio M, Lali R, Paré G. Le A, et al. Curr Atheroscler Rep. 2024 Jun;26(6):189-203. doi: 10.1007/s11883-024-01200-y. Epub 2024 Apr 4. Curr Atheroscler Rep. 2024. PMID: 38573470 Review.
A prenatal skin atlas reveals immune regulation of human skin morphogenesis.
Gopee NH, Winheim E, Olabi B, Admane C, Foster AR, Huang N, Botting RA, Torabi F, Sumanaweera D, Le AP, Kim J, Verger L, Stephenson E, Adão D, Ganier C, Gim KY, Serdy SA, Deakin C, Goh I, Steele L, Annusver K, Miah MU, Tun WM, Moghimi P, Kwakwa KA, Li T, Basurto Lozada D, Rumney B, Tudor CL, Roberts K, Chipampe NJ, Sidhpura K, Englebert J, Jardine L, Reynolds G, Rose A, Rowe V, Pritchard S, Mulas I, Fletcher J, Popescu DM, Poyner E, Dubois A, Guy A, Filby A, Lisgo S, Barker RA, Glass IA, Park JE, Vento-Tormo R, Nikolova MT, He P, Lawrence JEG, Moore J, Ballereau S, Hale CB, Shanmugiah V, Horsfall D, Rajan N, McGrath JA, O'Toole EA, Treutlein B, Bayraktar O, Kasper M, Progatzky F, Mazin P, Lee J, Gambardella L, Koehler KR, Teichmann SA, Haniffa M. Gopee NH, et al. Among authors: le ap. Nature. 2024 Nov;635(8039):679-689. doi: 10.1038/s41586-024-08002-x. Epub 2024 Oct 16. Nature. 2024. PMID: 39415002 Free PMC article.
Dual regulation of mitochondrial fusion by Parkin-PINK1 and OMA1.
Yamada T, Ikeda A, Murata D, Wang H, Zhang C, Khare P, Adachi Y, Ito F, Quirós PM, Blackshaw S, López-Otín C, Langer T, Chan DC, Le A, Dawson VL, Dawson TM, Iijima M, Sesaki H. Yamada T, et al. Among authors: le a. Nature. 2025 Mar;639(8055):776-783. doi: 10.1038/s41586-025-08590-2. Epub 2025 Feb 19. Nature. 2025. PMID: 39972141 Free PMC article.
Surrogate Adiposity Markers and Mortality.
Khan I, Chong M, Le A, Mohammadi-Shemirani P, Morton R, Brinza C, Kiflen M, Narula S, Akhabir L, Mao S, Morrison K, Pigeyre M, Paré G. Khan I, et al. Among authors: le a. JAMA Netw Open. 2023 Sep 5;6(9):e2334836. doi: 10.1001/jamanetworkopen.2023.34836. JAMA Netw Open. 2023. PMID: 37728925 Free PMC article.
Comprehensive proteogenomic characterization of rare kidney tumors.
Li GX, Chen L, Hsiao Y, Mannan R, Zhang Y, Luo J, Petralia F, Cho H, Hosseini N, Leprevost FDV, Calinawan A, Li Y, Anand S, Dagar A, Geffen Y, Kumar-Sinha C, Chugh S, Le A, Ponce S, Guo S, Zhang C, Schnaubelt M, Al Deen NN, Chen F, Caravan W, Houston A, Hopkins A, Newton CJ, Wang X, Polasky DA, Haynes S, Yu F, Jing X, Chen S, Robles AI, Mesri M, Thiagarajan M, An E, Getz GA, Linehan WM, Hostetter G, Jewell SD, Chan DW, Wang P, Omenn GS, Mehra R, Ricketts CJ, Ding L, Chinnaiyan AM, Cieslik MP, Dhanasekaran SM, Zhang H, Nesvizhskii AI; Clinical Proteomic Tumor Analysis Consortium. Li GX, et al. Among authors: le a. Cell Rep Med. 2024 May 21;5(5):101547. doi: 10.1016/j.xcrm.2024.101547. Epub 2024 May 3. Cell Rep Med. 2024. PMID: 38703764 Free PMC article.
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM; INSIGHT 2 investigators. Wu YL, et al. Among authors: le at. Lancet Oncol. 2024 Aug;25(8):989-1002. doi: 10.1016/S1470-2045(24)00270-5. Lancet Oncol. 2024. PMID: 39089305 Clinical Trial.
1,882 results